Rokit Healthcare Enters Large-Scale Multi-Center Clinical Trial for World's First AI-Powered Cartilage Regeneration Bioprinting Platform

Rokit Healthcare (KOSDAQ: 376900) has initiated a large-scale, multi-center clinical trial for its AI-driven cartilage regeneration bioprinting platform, designated TCW (Timeless Cartilage, Comfortable Work). The trial, which received approval from the Institutional Review Board (IRB) on May 4, 2026, will enroll over 100 patients across 13 hospitals. The platform integrates Rokit's proprietary AI-based 3D bioprinting technology with a novel approach using the patient's own infrapatellar fat pad (IFP) as the cell source, which is harvested arthroscopically, processed into a bioink, and printed into a customized cartilage implant. The system also features an in-situ printing capability, allowing the bioprinter to deposit the cell-laden scaffold directly into the defect site during a single surgical procedure, eliminating the need for a separate pre-implantation culture step.

This trial represents a significant step in the bioprinting segment, moving from proof-of-concept and small-scale studies toward the kind of rigorous, multi-site clinical validation required for eventual regulatory approval. The use of AI to analyze patient imaging data and generate a patient-specific 3D printing path in real time addresses a key bottleneck in personalized regenerative medicine: the ability to produce an anatomically precise, viable construct at the point of care. If successful, this platform could challenge the current standard of care for cartilage repair — microfracture and autologous chondrocyte implantation (ACI) — both of which have limitations in long-term durability and tissue quality. The trial's scale and the use of the IFP, a readily accessible and immunologically favorable cell source, position Rokit Healthcare as a frontrunner in the race to commercialize a clinically viable, off-the-shelf bioprinted cartilage solution.

For Rokit Healthcare, the immediate priority is execution: enrolling the full cohort of patients across 13 sites while maintaining consistent print quality and cell viability. The company must also demonstrate that the AI-driven in-situ printing workflow can be reliably replicated across different surgeons and hospital settings. For the broader bioprinting field, this trial will provide one of the first large-scale datasets on the safety and efficacy of a fully integrated AI-bioprinting platform for a high-demand orthopedic application. The results will either validate the thesis that point-of-care bioprinting can overcome the logistical and biological hurdles that have kept the field in the lab, or they will reveal the practical limits of the approach.